Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COMPANY IS WINDING DOWN GLOBAL ENROLLMENT FOR THE RASOLUTE 302 CLINICAL TRIAL STUDYING DARAXONRASIB IN PATIENTS WITH PREVIOUSLY TREATED PDAC AND REMAINS ON TRACK FOR DATA READOUT IN 2026 COMPANY HAS INITIATED RASOLUTE 304, A PHASE 3 CLINICAL TRIAL OF DARAXONRASIB AS ADJUVANT TREATMENT FOR PATIENTS WITH RESECTABLE PDAC, AND REMAINS ON TRACK TO INITIATE RASOLUTE 303 FOR PATIENTS WITH FIRST LINE METASTATIC PDAC THIS YEAR DARAXONRASIB HAS RECEIVED FDA BREAKTHROUGH THERAPY DESIGNATION, ORPHAN DRUG DESIGNATION AND A COMMISSIONER'S NATIONAL PRIORITY VOUCHER NEW LEADERSHIP APPOINTMENTS STRENGTHENED GLOBAL DEVELOPMENT AND COMMERCIALIZATION CAPABILITIES REVOLUTION MEDICINES TO HOLD WEBCAST TODAY AT 4:30 P.M. EASTERN TIME REDWOOD CITY, CALIF.

REVOLUTION MEDICINES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND UPDATE ON CORPORATE PROGRESS

REDWOOD CITY, CALIF., NOV. 04, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT MARK A.

REVOLUTION MEDICINES TO PARTICIPATE IN NOVEMBER 2025 INVESTOR CONFERENCES

REDWOOD CITY, CALIF., OCT. 29, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2025 ON WEDNESDAY, NOVEMBER 5, 2025, AFTER MARKET CLOSE. AT 4:30 P.M. ET THAT DAY (1:30 P.M. PT), MEMBERS OF REVOLUTION MEDICINES' SENIOR MANAGEMENT TEAM WILL HOST A WEBCAST TO DISCUSS THE FINANCIAL RESULTS FOR THE QUARTER AND PROVIDE AN UPDATE ON CORPORATE PROGRESS.

REVOLUTION MEDICINES TO REPORT FINANCIAL RESULTS FOR THIRD QUARTER 2025 AFTER MARKET CLOSE ON NOVEMBER 5, 2025

REDWOOD CITY, CALIF., OCT. 27, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED ORPHAN DRUG DESIGNATION TO DARAXONRASIB, THE COMPANY'S RAS(ON) MULTI-SELECTIVE INHIBITOR, FOR THE TREATMENT OF PANCREATIC CANCER.

REVOLUTION MEDICINES' RAS(ON) MULTI-SELECTIVE INHIBITOR DARAXONRASIB GRANTED U.S. FDA ORPHAN DRUG DESIGNATION IN PANCREATIC CANCER

REDWOOD CITY, CALIF., OCT. 22, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED UPDATED CLINICAL DATA FOR ELIRONRASIB, A RAS(ON) G12C-SELECTIVE INHIBITOR, IN PREVIOUSLY TREATED PATIENTS WITH KRAS G12C NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD RECEIVED A PRIOR KRAS(OFF) G12C INHIBITOR. THESE RESULTS WILL BE HIGHLIGHTED IN AN ORAL PRESENTATION AT THE AACR-NCI-EORTC SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS IN BOSTON, OCTOBER 23-25.

REVOLUTION MEDICINES TO PRESENT UPDATED ELIRONRASIB SAFETY AND EFFICACY DATA IN PATIENTS WITH KRAS G12C NON-SMALL CELL LUNG CANCER FOLLOWING TREATMENT WITH A KRAS(OFF) G12C INHIBITOR

REDWOOD CITY, CALIF., OCT. 16, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED A NON-TRANSFERRABLE VOUCHER FOR DARAXONRASIB (RMC-6236), THE COMPANY'S RAS(ON) MULTI-SELECTIVE INHIBITOR, UNDER THE COMMISSIONER'S NATIONAL PRIORITY VOUCHER (CNPV) PILOT PROGRAM.

REVOLUTION MEDICINES AWARDED VOUCHER FOR DARAXONRASIB (RMC-6236) UNDER FDA COMMISSIONER'S NATIONAL PRIORITY VOUCHER PILOT PROGRAM

REDWOOD CITY, CALIF., SEPT. 29, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THE APPOINTMENT OF ALAN SANDLER, M.D. INTO THE NEWLY CREATED ROLE OF CHIEF DEVELOPMENT OFFICER, AS WELL AS THE APPOINTMENT OF REGIONAL GENERAL MANAGERS IN THE U.S. AND EUROPE.

REVOLUTION MEDICINES ANNOUNCES KEY LEADERSHIP ADDITIONS, INCLUDING ALAN SANDLER, M.D. AS CHIEF DEVELOPMENT OFFICER

LONG-TERM FOLLOW-UP DATA FOR DARAXONRASIB MONOTHERAPY IN SECOND LINE METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA REINFORCES PROMISING CLINICAL ACTIVITY AND DURABILITY

REVOLUTION MEDICINES SHARES NEW CLINICAL RESULTS SUPPORTING INITIATION OF RASOLUTE 303, A GLOBAL PHASE 3 REGISTRATIONAL TRIAL OF DARAXONRASIB IN FIRST LINE METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

REDWOOD CITY, CALIF., AUG. 06, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025, AND PROVIDED AN UPDATE ON CORPORATE PROGRESS.

REVOLUTION MEDICINES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND UPDATE ON CORPORATE PROGRESS

REDWOOD CITY, CALIF., JULY 30, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT IT WILL REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025 ON WEDNESDAY, AUGUST 6, 2025, AFTER MARKET CLOSE. AT 4:30 P.M. ET THAT DAY (1:30 P.M. PT), MEMBERS OF REVOLUTION MEDICINES' SENIOR MANAGEMENT TEAM WILL HOST A WEBCAST TO DISCUSS THE FINANCIAL RESULTS FOR THE QUARTER AND PROVIDE AN UPDATE ON CORPORATE PROGRESS.

REVOLUTION MEDICINES TO REPORT FINANCIAL RESULTS FOR SECOND QUARTER 2025 AFTER MARKET CLOSE ON AUGUST 6, 2025

REDWOOD CITY, CALIF., JULY 24, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THE PUBLICATION OF A PEER-REVIEWED RESEARCH PAPER IN SCIENCE. THE SCIENTIFIC PAPER DETAILS THE DISCOVERY AND DEVELOPMENT OF ZOLDONRASIB (RMC-9805), A RAS(ON) G12D-SELECTIVE COVALENT INHIBITOR.

REVOLUTION MEDICINES ANNOUNCES PUBLICATION OF A PEER-REVIEWED RESEARCH PAPER IN SCIENCE ON THE DISCOVERY AND DEVELOPMENT OF ZOLDONRASIB, A RAS(ON) G12D-SELECTIVE INHIBITOR

BREAKTHROUGH THERAPY DESIGNATION GRANTED TO ELIRONRASIB FOR THE TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY AND IMMUNOTHERAPY BUT HAVE NOT BEEN PREVIOUSLY TREATED WITH A KRAS G12C INHIBITOR DESIGNATION BASED ON ENCOURAGING CLINICAL DATA OBSERVED WITH ELIRONRASIB IN PATIENTS WITH ADVANCED KRAS G12C NON-SMALL CELL LUNG CANCER REDWOOD CITY, CALIF., JULY 23, 2025 (GLOBE NEWSWIRE) -- REVOLUTION MEDICINES, INC. (NASDAQ: RVMD), A LATE-STAGE CLINICAL ONCOLOGY COMPANY DEVELOPING TARGETED THERAPIES FOR PATIENTS WITH RAS-ADDICTED CANCERS, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED BREAKTHROUGH THERAPY DESIGNATION TO ELIRONRASIB, THE COMPANY'S RAS(ON) G12C-SELECTIVE INHIBITOR, FOR THE TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY AND IMMUNOTHERAPY BUT HAVE NOT BEEN PREVIOUSLY TREATED WITH A KRAS G12C INHIBITOR.

Revolution Medicines, Inc.

RVMD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Revolution Medicines, Inc.

RVMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RVMD